Premenstrual Syndrome Treatment Market

Premenstrual Syndrome Treatment Market Size Survey Report – In a Glance

As per the survey report on global Premenstrual syndrome treatment market, the market is projected to foresee a CAGR of CAGR value 3.7% between 2024-2033, and further generate a market size of USD 2.1 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 1.4 billion revenue.

• The global Premenstrual syndrome treatment market is projected to grow on account of the uptick in PMS cases.
• In Japan, the Premenstrual syndrome treatment market growth can be attributed to the heightened health awareness.
• KDMI analyst’s growth analysis foresees low market demand in developing nations to challenge the market growth.
• North America, having the highest market share in the Premenstrual syndrome treatment market, is projected to dominate the global market.

Premenstrual Syndrome Treatment Market Analysis

Premenstrual syndrome (PMS) is a health condition affecting women in their fertile years consisting of a combination of symptoms before their monthly menstrual period. It brings about physical, psychological, and emotional distress that includes symptoms like headaches, back pain, weight gain, bloating, fatigue, mood swings, abdominal pain, swelling, and restlessness. Some women may have such severe symptoms that they need to take leave from work or school, while others have milder signs. Worldwide, around 47.8% of women in their child-bearing age are experiencing PMS and out of these, approximately 20% suffer from symptoms severe enough to disrupt their daily routines. Therefore, an uptick in PMS cases drives the need for remedies or treatments leading to increased sales of medicines, health supplements, and wellness products, thereby, accelerating the PMS treatment market growth. Dr. Reddy’s Laboratories Ltd, Pfizer Inc., GlaxoSmithKline Plc., are some of the significant parties in the global market for Premenstrual syndrome treatment.

Analyst’s Observation on Japan Premenstrual Syndrome Treatment Market Survey

With a rapidly aging society and rising health consciousness, Japan provides a promising market for wellness-focused products and services. For marketing professionals, the gap between awareness and application presents a key opportunity. Solutions that offer simple and easy-to-adapt self-care practices are likely to gain traction. Besides, more than 80% of women in the country are concerned about their menstrual health and the market growth for Premenstrual syndrome treatment is mainly due to the heightened health awareness within the nation. Therefore, the growing health consciousness drives the PMS treatment market by enhancing demand for medical treatments, herbal supplements, and symptom management products.

Premenstrual Syndrome Treatment Market Growth Drivers and Challenges

Growth Drivers

Increasing women’s employment:

The surge in female workforce has been a major economic milestone in the last hundred years. Moreover, promoting economic equality for women benefits businesses. Companies gain greatly by creating more employment opportunities for women and embracing greater female participation. According to reports, women dominate the workforce in Healthcare and Care Services (62.1%), Education (54.4%), Consumer Services (53.1%), and Government and Public Sector (50.7%), in 2024. As female employment rises, awareness of premenstrual syndrome (PMS) and its challenges grows as well. As a result, female employees look for solutions to ease symptoms and stay productive in their job life. Even companies also understand the importance of better healthcare support. Hence, this increasing demand for medications, dietary supplements, and wellness products strengthens the overall PMS treatment market.

Surging medical spending:

As medical expense grows, more PMS-affected women seek medical support from general physicians, gynecologists, and other healthcare providers for proper diagnosis and treatment. Increased medical spending is often linked to better access to both drug-based treatments and non-pharmacological alternative therapies, such as hormonal therapy and cognitive behavioral therapy. In addition to that, it also supports medical research for improved PMS treatment options. As stated in the WTW Global Medical Trends Survey, insurers foresee a 10.4% spike in healthcare expenses in 2025. Escalating medical costs expands healthcare access, helping more women with PMS receive proper diagnosis, treatment, and care. It also supports innovative treatment solutions including drugs as well as natural remedies. Thus, this surging medical spending drives new discoveries, ultimately propelling the PMS treatment market worldwide.

Restraints

Low market demand in developing nations:

In many parts of the world, especially in less-developed regions, patriarchal societies, and developing nations like Middle East, menstruation is still a strong social taboo. Therefore, low market demand in less-developed areas curtails investment, awareness, and distribution, hindering PMS treatment market worldwide due to low affordability and poor healthcare infrastructure.

Lack of standardized treatment protocols:

The lack of standardized treatment approach for premenstrual syndrome, diagnosing, and managing the condition becomes challenging, reducing access to effective solutions. Both patients and healthcare providers find it difficult to rely on available options. This uncertainty hinders market growth all over the world, as the demand for proven options remains largely unsatisfied.

Premenstrual Syndrome Treatment Market Segmentation

Our experts at KD Market Insights have segmented the global Premenstrual syndrome treatment market research report as:

Premenstrual Syndrome Treatment Market Regional Synopsis

North America is at the forefront of the premenstrual syndrome (PMS) market and is majorly driven by its strong research and development activities. Besides that, higher prevalence of PMS, easy access to therapeutics, the progressive healthcare systems, availability of skilled medical personnel increased awareness among the public and favorable government initiatives in Canada and the United States further fuels the market within the region. According to the American Psychiatric Association reports, the premenstrual symptoms are experienced by approximately 90% of women of reproductive age. The United States holds the largest share of the regional PMS treatment market within the given period because of the presence of pharmaceutical companies, rising women employment and increased adoption of innovative treatments along with promising drug development pipeline in the country. Besides, women contribute an integral part in the U.S. economy, now comprising approximately 50% of the workforce.

Asia-Pacific (APAC) is encountering the quickest market surge during the forecasted period. The region functions as a central point for pharmaceutical businesses. This is mainly due to expansive distribution channels and trade connections. Furthermore, the market is also steered by the increasing use of PMS generic drugs, consumer demands, economic expansion and progressing healthcare infrastructure. India is also upgrading the PMS treatment market due to its massive population, fast economic progression, increasing public awareness about PMS, greater healthcare investments and strengthened healthcare systems. In addition to that, Japan’s economic progress is likely to expand at a rate beyond its expected growth capacity. China is also contributing a significant part to the regional market. It has implemented the world’s largest planned urban transformation program, thereby, promoting healthcare development. Also, numerous policies have supported its overall healthcare framework and economic growth goals.

In Europe, the existence of government organizations supporting early detection and preventive screening of PMS are mainly expected to drive PMS market expansion in the coming future. Moreover, the UK is at the forefront of the development of the market in the region due to its increasing improved diagnostics and strong healthcare policies. Several factors are responsible for the market evolution in the area such as the rising occurrence of PMS, growing PMS awareness, and expanding availability of medical solutions.

Premenstrual Syndrome Treatment Market Competitive Landscape

Some of the key players who top the global Premenstrual syndrome treatment market share:

• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• MetP Pharma AG
• GlaxoSmithKline
• Eli Lilly and Company
• Novartis International AG
• Asarina Pharma AB
• Merck
• Bayer AG
• Mylan N.V.
• Pherin Pharmaceuticals
• Umecrine Mood AB
• Chattem Inc.
• H. Lundbeck A/S

1. Executive Summary

1.1. Market Overview

1.2. Key Findings

1.3. Market Trends

1.4. Market Outlook

2. Introduction

2.1. Scope of the Report

2.2. Research Methodology

2.3. Definitions and Assumptions

2.4. Acronyms and Abbreviations

3. Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities

3.4. Challenges

4. Global Premenstrual Syndrome Treatment Market

4.1. Market Overview

4.2. Market Size and Forecast

4.3. Market Segmentation

4.3.1. By Drug type

4.3.2. By Type

4.3.3. By Distribution channel

4.3.4. By Region

5. Market Segmentation by Drug type

5.1.1. Analgesics

5.1.2. Antidepressants

5.1.3. Oral Contraceptives

5.1.4. Ovarian Suppression Agents

5.1.5. Others

6. Market Segmentation by Type

6.1.1. Prescription

6.1.2. OTC

7. Market Segmentation by Distribution channel

7.1.1. Hospital Pharmacies

7.1.2. Drug Stores and Retail Pharmacies

7.1.3. Online Providers

8. Regional Analysis

8.1. North America

8.1.1. United States

8.1.1.1. Market Size and Forecast

8.1.1.2. Key Trends and Developments

8.1.1.3. Market Analysis by Drug type, Type, and Distribution channel

8.1.2. Canada

8.1.2.1. Market Size and Forecast

8.1.2.2. Key Trends and Developments

8.1.2.3. Market Analysis by Drug type, Type, and Distribution channel

8.1.3. Mexico

8.1.3.1. Market Size and Forecast

8.1.3.2. Key Trends and Developments

8.1.3.3. Market Analysis by Drug type, Type, and Distribution channel

8.2. Europe

8.2.1. United Kingdom

8.2.1.1. Market Size and Forecast

8.2.1.2. Key Trends and Developments

8.2.1.3. Market Analysis by Drug type, Type, and Distribution channel

8.2.2.Germany

8.2.2.1. Market Size and Forecast

8.2.2.2. Key Trends and Developments

8.2.2.3. Market Analysis by Drug type, Type, and Distribution channel

8.2.3.France

8.2.3.1. Market Size and Forecast

8.2.3.2. Key Trends and Developments

8.2.3.3. Market Analysis by Drug type, Type, and Distribution channel

8.2.4.Italy

8.2.4.1. Market Size and Forecast

8.2.4.2. Key Trends and Developments

8.2.4.3. Market Analysis by Drug type, Type, and Distribution channel

8.2.5.Spain

8.2.5.1. Market Size and Forecast

8.2.5.2. Key Trends and Developments

8.2.5.3. Market Analysis by Drug type, Type, and Distribution channel

8.2.6.Rest of Europe

8.2.6.1. Market Size and Forecast

8.2.6.2. Key Trends and Developments

8.2.6.3. Market Analysis by Drug type, Type, and Distribution channel

8.3. Asia Pacific

8.3.1. China

8.3.1.1. Market Size and Forecast

8.3.1.2. Key Trends and Developments

8.3.1.3. Market Analysis by Drug type, Type, and Distribution channel

8.3.2.Japan

8.3.2.1. Market Size and Forecast

8.3.2.2. Key Trends and Developments

8.3.2.3. Market Analysis by Drug type, Type, and Distribution channel

8.3.3.India

8.3.3.1. Market Size and Forecast

8.3.3.2. Key Trends and Developments

8.3.3.3. Market Analysis by Drug type, Type, and Distribution channel

8.3.4.Australia

8.3.4.1. Market Size and Forecast

8.3.4.2. Key Trends and Developments

8.3.4.3. Market Analysis by Drug type, Type, and Distribution channel

8.3.4.4. South Korea

8.3.4.5. Market Size and Forecast

8.3.4.6. Key Trends and Developments

8.3.4.7. Market Analysis by Drug type, Type, and Distribution channel

8.3.5.Rest of Asia Pacific

8.3.5.1. Market Size and Forecast

8.3.5.2. Key Trends and Developments

8.3.5.3. Market Analysis by Drug type, Type, and Distribution channel

8.4. Latin America

8.4.1. Brazil

8.4.1.1. Market Size and Forecast

8.4.1.2. Key Trends and Developments

8.4.1.3. Market Analysis by Drug type, Type, and Distribution channel

8.4.2.Argentina

8.4.2.1. Market Size and Forecast

8.4.2.2. Key Trends and Developments

8.4.2.3. Market Analysis by Drug type, Type, and Distribution channel

8.4.3.Colombia

8.4.3.1. Market Size and Forecast

8.4.3.2. Key Trends and Developments

8.4.3.3. Market Analysis by Drug type, Type, and Distribution channel

8.4.4.Rest of Latin America

8.4.4.1. Market Size and Forecast

8.4.4.2. Key Trends and Developments

8.4.4.3. Market Analysis by Drug type, Type, and Distribution channel

8.5. Middle East & Africa

8.5.1. South Africa

8.5.1.1. Market Size and Forecast

8.5.1.2. Key Trends and Developments

8.5.1.3. Market Analysis by Drug type, Type, and Distribution channel

8.5.2.Saudi Arabia

8.5.2.1. Market Size and Forecast

8.5.2.2. Key Trends and Developments

8.5.2.3. Market Analysis by Drug type, Type, and Distribution channel

8.5.3.UAE

8.5.3.1. Market Size and Forecast

8.5.3.2. Key Trends and Developments

8.5.3.3. Market Analysis by Drug type, Type, and Distribution channel

8.5.4.Rest of Middle East & Africa

8.5.4.1. Market Size and Forecast

8.5.4.2. Key Trends and Developments

8.5.4.3. Market Analysis by Drug type, Type, and Distribution channel

9. Competitive Landscape

9.1. Market Share Analysis

9.2. Company Profiles

9.3. Teva Pharmaceutical Industries Ltd.

9.4. Pfizer Inc.

9.5. MetP Pharma AG

9.6. GlaxoSmithKline

9.7. Eli Lilly and Company

9.8. Novartis International AG

9.9. Asarina Pharma AB

9.10.Merck

9.11. Bayer AG

10. Strategic Recommendations

11. Appendix

11.1. List of Tables

11.2. List of Figures

12.References